Scribe Biosciences

Scribe Biosciences was a private life science tools company focused on single-cell analysis technologies for immunotherapy research and related biomedical applications. Its core technology centered on printed droplet microfluidics and the Microenvironment on Demand platform, which enabled deterministic handling of droplets and single cells for functional and genomic profiling. The company developed tools and assays for studying cell-cell interactions, antibody discovery, hybridoma generation, and cytotoxicity assays relevant to CAR-T and other cell therapies. Scribe Biosciences appeared to operate as a platform and research-tools company rather than a therapeutic drug developer, with grants, accelerator support, and patent activity supporting its development. Available company-data sources indicate the business is now out of business as of 2025.